Chronic partial TrkB activation reduces seizures and mortality in a mouse model of Dravet syndrome.
Chronic partial TrkB activation reduces seizures and mortality in a mouse model of Dravet syndrome.
复制标题
慢性部分TrkB激活降低Dravet综合征小鼠模型中的癫痫发作和死亡率
DOI：
10.1073/pnas.2022726119
复制
发表时间：
2022-02-15
影响因子：
11.1
通讯作者：
Prince DA
中科院分区：
文献类型：
--
作者：
Gu F;Parada I;Yang T;Longo FM;Prince DA
Dravet syndrome (DS) is a severe childhood epileptic encephalopathy characterized by intractable seizures and comorbidities, including a high rate of premature mortality. DS is mainly caused by loss-of-function mutations of the Scn1a gene encoding sodium channel Nav1.1 that is predominantly expressed in inhibitory parvalbumin-containing (PV) interneurons. Decreased Nav1.1 impairs PV cell function, causing DS phenotypes. Effective pharmacological therapy targeting defective PV interneurons is currently not available. This study demonstrated that early treatment with a partial TrkB receptor agonist, LM22A-4, increased Nav1.1 expression, improved PV interneuron function, and reduced seizure occurrence and mortality rate in DS mice, suggesting a potential therapy for DS. Dravet syndrome (DS) is one of the most severe childhood epilepsies, characterized by intractable seizures and comorbidities including cognitive and social dysfunction and high premature mortality. DS is mainly caused by loss-of-function mutations in the Scn1a gene encoding Nav1.1 that is predominantly expressed in inhibitory parvalbumin-containing (PV) interneurons. Decreased Nav1.1 impairs PV cell function, contributing to DS phenotypes. Effective pharmacological therapy that targets defective PV interneurons is not available. The known role of brain-derived neurotrophic factor (BDNF) in the development and maintenance of interneurons, together with our previous results showing improved PV interneuronal function and antiepileptogenic effects of a TrkB receptor agonist in a posttraumatic epilepsy model, led to the hypothesis that early treatment with a TrkB receptor agonist might prevent or reduce seizure activity in DS mice. To test this hypothesis, we treated DS mice with LM22A-4 (LM), a partial agonist at the BDNF TrkB receptor, for 7 d starting at postnatal day 13 (P13), before the onset of spontaneous seizures. Results from immunohistochemistry, Western blot, whole-cell patch-clamp recording, and in vivo seizure monitoring showed that LM treatment increased the number of perisomatic PV interneuronal synapses around cortical pyramidal cells in layer V, upregulated Nav1.1 in PV neurons, increased inhibitory synaptic transmission, and decreased seizures and the mortality rate in DS mice. The results suggest that early treatment with a partial TrkB receptor agonist may be a promising therapeutic approach to enhance PV interneuron function and reduce epileptogenesis and premature death in DS.
登录
查看更多内容
影响因子：
5.8
作者：
Chow, Chun Yuen;Chin, Yanni K. Y.;King, Glenn F.
通讯作者：
King, Glenn F.
影响因子：
5.6
作者：
Cross, J. Helen;Caraballo, Roberto H.;Lagae, Lieven
通讯作者：
Lagae, Lieven
影响因子：
8.3
作者：
Han J;Pollak J;Yang T;Siddiqui MR;Doyle KP;Taravosh-Lahn K;Cekanaviciute E;Han A;Goodman JZ;Jones B;Jing D;Massa SM;Longo FM;Buckwalter MS
通讯作者：
Buckwalter MS
影响因子：
14.5
作者：
Griffin, Aliesha;Hamling, Kyla R.;Baraban, Scott C.
通讯作者：
Baraban, Scott C.
影响因子：
2.5
作者：
Faria, Leonardo C.;Prince, David A.
通讯作者：
Prince, David A.